Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2007

To view an abstract, select an author from the vertical list on the left.

2007 Grant - Gordon

Cell-Based Therapies Using Transgenic Mice

Marcia Gordon, Ph.D.
University of South Florida
Tampa, Florida

2007 Investigator-Initiated Research Grant

One strategy that has been proposed for treating Alzheimer's disease is to utilize enzymes to remove beta-amyloid from the brain. Beta-amyloid is a protein fragment that is a primary component of amyloid plaques, one of the characteristic features of Alzheimer's disease. One enzyme that degrades beta-amyloid is neprilysin, but methods to introduce this enzyme into the brain have been hampered by the risks of surgery or by immune reactions and cancer risks associated with molecular methods.

Marcia Gordon, Ph.D., and colleagues have proposed to introduce neprilysin into the brain by using a patient's own cells to carry the gene for the protein. The researchers plan to evaluate the use of monocytes, which are a type of cell found in the blood, for carrying the neprilysin gene into the brain and expressing it there. Monocytes have a number of advantages that make them well-suited for this purpose.

To test the feasibility of this method, Dr. Gordon and colleagues plan to study mice that express genes that make them susceptible to an Alzheimer-like condition and that cause deposition of beta-amyloid in the brain. Using these mice, they will retrieve the animal's own monocytes, introduce the gene for neprilysin into the cells, and then reintroduce the cells into the animal's blood stream. They will then evaluate the efficacy and safety of this procedure for removing beta-amyloid from the brain. These studies could lead to the development of methods to remove beta-amyloid from the brain of people affected by Alzheimer's disease.  

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.